Research out of the Yale School of Public Health in New Haven, Conn., has revealed a relationship between rosiglitazone, a type 2 diabetes drug, and heart disease.

A recent review of pivotal cancer drug trials suggests that CVD and adverse cardiovascular outcomes are underreported in studies of new cancer therapies, despite an increasing risk of cardiotoxicity in oncological drugs.

Prolonged cardiac surgery wait times in Wales are forcing physicians to cherry-pick patients for treatment elsewhere, the BBC reported this month.

A beta-blocker and aspirin combination may help attenuate the heightened CVD risk observed in people who have recently lost a loved one, according to research published in the American Heart Journal in February.

Medical AI company Caption Health announced Feb. 7 that the FDA had authorized marketing for its Caption Guidance software.

The Heart Rhythm Society and Elsevier have partnered to launch the Cardiovascular Digital Health Journal, a peer-review, open-access publication that will debut in July.

Physicians who treat individuals with AFib may mistake gastrointestinal bleeding as a side effect of their patients’ blood thinners when it may, in fact, be an early warning sign for bowel cancer, according to a new study.

Over half of heart patients on a triple-drug regimen of ACE inhibitors, statins and either calcium channel blockers or aspirin are nonadherent to their medications, researchers reported in the American Journal of Cardiology Feb. 6.

A recent analysis of FitBit data suggests there is no one “normal” resting heart rate for humans, with users’ average HR coming in at between 40 and 109 beats per minute, Discover Magazine reported.

Research out of Ireland suggests end-of-life care needs will nearly double over the next three decades, corresponding to an increase of 84% by 2046.